Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates

Abstract excerpt

Pompe disease (PD) is a severe neuromuscular disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). PD is currently treated with enzyme replacement therapy (ERT) with intravenous infusions of recombinant human GAA (rhGAA). Although the introduction of ERT represents a breakthrough in the management of PD, the approach suffers from several shortcomings. Here, we developed a mouse model...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Genetics and Neurodevelopmental Disorders
• Share to Glycogen Storage Diseases and Myoclonus
• Share to Lysosomal Storage Disorders Research